Gilead expects that the internal research and development assets expenses generated from the Q2 acquisition will reach 11.2 billion US dollars.

Gilead stated that the $11.2 billion in internal research and development asset expenses formed from the acquisition in the second quarter correspond to a one-time gain or loss of approximately $9.12 per share, adjusted for GAAP and tax impact related to the transaction.